Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study.


Ailawadhi S., Špička I., Spencer A., Lu J., Oriol A., Ling S., ...Daha Fazla

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025 (SCI-Expanded) identifier